Latest Breaking News On - Increased survival observed - Page 1 : comparemela.com

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

- Primary Endpoint of Safety and Efficacy Met with Clinical Activity and Increased Survival Observed - - 70.3 Weeks Median Overall Survival for Patients Treated with Combination Therapy; Median.

United statesAngelos stergiouBruce mackleLifesci advisorsGlobenewswire incLife sciences group incNational cancer instituteGenfleet therapeutics shanghai incBristol myers squibbMemorial sloan kettering cancer centerEfficacy metClinical activityIncreased survival observedMedian overall survivalPatients treatedCombination therapy

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed

-Primary Endpoint of Safety and Efficacy Met with Clinical Activity and Increased Survival Observed -

United statesBruce mackleAngelos stergiouLife sciences group incNational cancer instituteGenfleet therapeutics shanghai incMemorial sloan kettering cancer centerBristol myers squibbLifesci advisorsPrimary endpointEfficacy metClinical activityIncreased survival observedMedian overall survivalPatients treatedCombination therapy

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesBruce mackleAngelos stergiouNational cancer instituteLife sciences reports positiveLife sciences group incMemorial sloan kettering cancer centerBristol myers squibbGenfleet therapeutics shanghai incLifesci advisorsSurvival dataCompleted phaseGalinpepimuts combinedAdvanced malignant pleuralEfficacy metClinical activity